<![CDATA[Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026]]>

Advertisement Commentary|Articles|May 8, 2026 Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026 Author(s)Ashling Wahner Fact checked by: Chris Ryan Listen0:00 / 0:00 Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ASCO 2026. Advertisement As the 2026 ASCO Annual Meeting approaches, we’re preparing to see several potentially practice-informing breast cancer presentations spanning hormone receptor (HR)–positive, HER2-positive, triple-negative, and early-stage treatment strategies. Several late-breaking abstracts will explore key questions surrounding treatment sequencing, endocrine resistance, antibody-drug conjugates, and novel HER2-targeted therapies.We asked readers to share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at this year’s meeting. To read more about these studies and additional abstracts of interest ahead of ASCO 2026, read our in-depth previews on the top triple-negative breast cancer (TNBC) and HR-positive and HER2-positive presentations.Poll: Which breast cancer abstract are you most excited to see presented at the 2026 ASCO Annual Meeting?LBA1000: PFS2 data from ASCENT-04LBA1007: PFS2 data from SERENA-6LBA1006: persevERA BCLBA660: anbenitamab + nab-docetaxel ± carboplatin in HER2+ early breast cancerAmong the most anticipated presentations is the phase 3 persevERA BC trial (NCT04546009), which is evaluating first-line giredestrant plus palbociclib (Ibrance) vs letrozole plus palbociclib in patients with estrogen receptor (ER)–positive, HER2-negative locally advanced or metastatic breast cancer. Although a March 2026 news release indicated that the trial did not meet its primary end point, interest remains high regarding whether a more potent endocrine therapy backbone can improve outcomes when paired with CDK4/6 inhibition.1 The presentation may also provide insight into whether oral selective ER degraders (SERDs) can benefit patients regardless of ESR1 mutation status, a key question in the evolving HR-positive treatment paradigm.Top Presentations to Watch at the 2026 ASCO Annual MeetingHR+ and HER2+ Breast CancerTriple-Negative Breast CancerLung CancerAdditional HR-positive breast cancer data will come from final time to second progression (PFS2) findings from the phase 3 SERENA-6 trial (NCT04964934), which is evaluating first-line camizestrant in patients with advanced breast cancer with emergent ESR1 mutations during treatment with an aromatase inhibitor and a CDK4/6 inhibitor ahead of radiographic disease progression. The study previously generated significant attention after reports that the FDA’s Oncologic Drugs Advisory Committee did not vote in favor of the clinical benefit of this treatment approach for the proposed indication based on available data.2 The field is now looking to the PFS2 analysis to better understand whether earlier intervention with camizestrant meaningfully alters long-term disease control and subsequent treatment outcomes.In triple-negative breast cancer (TNBC), updated findings from the phase 3 ASCENT-04 study (NCT05382286) will examine PFS2 data and outcomes with subsequent therapies among patients with previously untreated PD-L1–positive metastatic TNBC treated with sacituzumab govitecan-hziy (Trodelvy) plus pembrolizumab (Keytruda) vs chemotherapy plus pembrolizumab. Earlier analyses from the trial demonstrated progression-free survival benefits favoring the sacituzumab govitecan–based combination, helping fuel enthusiasm around moving TROP2-directed antibody-drug conjugates (ADCs) into earlier treatment lines. However, the forthcoming presentation may help answer a critical sequencing question: whether initiating sacituzumab govitecan in the frontline setting provides a durable advantage beyond first progression, or whether reserving the drug for later lines remains a reasonable strategy for some patients.Another highly anticipated abstract is LBA660, which will present findings from a randomized phase 3 study (KN026-004; NCT06747338) evaluating anbenitamab plus nab-docetaxel with or without carboplatin vs trastuzumab (Herceptin), pertuzumab (Perjeta), and docetaxel with or without carboplatin in patients with HER2-positive early or locally advanced breast cancer. The study is notable for using a comparator regimen that closely reflects standard practice in the United States, potentially increasing the clinical relevance of the findings. Investigators are also eager to learn more about anbenitamab, a biparatopic HER2-targeted antibody designed to bind 2 distinct HER2 epitopes, inhibit signaling activity, and promote HER2 degradation. This mechanism of action may offer an alternative HER2-directed treatment strategy associated with less toxicity compared with ADCs.On LinkedIn, respondents (n = 8) favored the SERENA-6 PFS2 results (75%), followed by the ASCENT-04 PFS2 data (25%). Results were slightly more varied on X, with respondents (n = 5) favoring the ASCENT-04 PFS2 readout (40%), followed by a tie between the SERENA-6 PFS2 data, the persevERA findings, and the LBA660 presentation (20% each).Poll: What breast cancer subtype or area are you most excited to learn more about at the 2026 ASCO Annual Meeting?HR-positive breast cancerHER2-positive breast cancerTNBCEarly-stage breast cancerOn LinkedIn, respondents (n = 68) favored TNBC (49%), followed by HR-positive (24%), HER2-positive (19%), and early-stage (9%) disease. Results were similar on X, with respondents (n = 7) favoring TNBC (57.1%), followed by a tie between HR-positive, HER2-positive, and early-stage disease (14.3% each).Collectively, these presentations underscore the rapid pace of therapeutic evolution across breast cancer subtypes. From refining endocrine approaches in HR-positive disease to optimizing sequencing strategies in TNBC and exploring novel HER2-targeted platforms in early-stage disease, ASCO 2026 is expected to generate important data that could shape future standards of care.ReferencesGenentech provides update on phase III persevErA study in ER-positive advanced breast cancer. News release. Genentech. March 8, 2026. Accessed May 8, 2026. https://www.gene.com/media/press-releases/15106/2026-03-08/genentech-provides-update-on-phase-iii-pApril 30, 2026 meeting of the Oncologic Drugs Advisory Committee (ODAC). FDA. Accessed May 8, 2026. https://www.youtube.com/live/taCx7enN7hk NewsletterStay up to date on the most recent and practice-changing oncology dataSubscribe Now! Advertisement Related ContentAdvertisementOncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 2026ByCaroline SeymourMay 8th 2026First-Line Danvatirsen Plus Pembrolizumab Fails to Improve Response Rates in Metastatic HNSCCByAshling Wahner May 8th 2026Mentorship Is Key to Advance the Next Generation of Oncology ResearchersByKyle Doherty May 7th 2026Women With Bladder Cancer Face Diagnostic Delays as Symptoms Mimic UTIs, Experts WarnByKyle Doherty May 7th 2026Daraxonrasib Monotherapy Elicits Meaningful Responses in Previously Treated, RAS-Mutated Pancreatic CancerByCourtney FlahertyMay 7th 2026 Latest CMEVideoProactive Adverse Event Management for HER2+ BTC TreatmentsRahul Gosain, MD, MBA; Rohit Gosain, MD; Rachna T. Shroff, MD, MS, FASCOView moreMultimediaCommunity Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for MelanomaYana G. Najjar, MD; Douglas B. Johnson, MD, MSCI; Rahul A. Sheth, MD, FSIR View moreVirtual EventWisconsin Association of Hematology and Oncology1 Session is Available!View moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Empire State Hematology & Oncology SocietySeth A. Wander, MD, PhD; Girish Kunapareddy, MDView moreVirtual EventArkansas Association of Cancer Professionals2 Sessions are Available!View moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | South Carolina Oncology SocietySeth A. Wander, MD, PhD; Kit Lu, MDView moreVideo19th Annual New York GU Cancers Congress®Maha Hussain, MD, FACP, FASCO; Daniel P. Petrylak, MDView moreIn-Person + Virtual EventGo to PER in ChicagoMay 29-31, 2026View moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Tennessee Oncology Practice SocietySeth A. Wander, MD, PhD; Kamel Abou Hussein, MDView moreVirtual EventKansas Society of Clinical Oncology1 Session is Available!View moreVideoA Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)Cindy Neunert, MD, MSCS; Hanny Al-Samkari, MD; Joseph Shatzel, MD, MCRView moreVideoEvolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular TestingEileen M. O’Reilly, MD; E. Gabriela Chiorean, MD, FASCO; Michael J. Pishvaian, MD, PhD; Brian Wolpin, MD, MPHView moreVideoCases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple MyelomaC. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MDView moreVideoTumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLCBalazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MDView moreVideoMedical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic ApproachesRami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MDView moreVideoPER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging StrategiesJonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhDView moreVideoMedical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted TherapiesVinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen J. Bagley, MD, MSCE; Angela Waanders, MD, MPH, MSView moreVideoMedical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple MyelomaC. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MDView moreVideoMedical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 DysregulationRebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhDView moreVideoCases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical InsightsGail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHSView moreVideoMedical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast CancerWilliam J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhDView moreVideoGI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal CancerJohn H. Strickler, MD; Stacey A. Cohen, MD; Aparna Parikh, MD; Kanwal P.S. Raghav, MBBS, MDView moreVideoBreast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer TreatmentJoyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCOView moreMultimediaEstablishing the Rationale for ADC and ICI Combinations in TNBCVirginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCOView moreMultimediaBreaking Down the Rationale for Targeting TROP2 in TNBCFilipa Lynce, MD; Rita Nanda, MDView moreMultimediaDissecting Clinical Trial and Real-World Data for ADCs in TNBCFilipa Lynce, MD; Rita Nanda, MDView moreMultimediaEvaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MDView moreAudioBreaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLCRahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MSView moreVideoOptimizing Treatment for Biliary Tract CancersGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreVideoCross-Disease Integration of Immunotherapy InnovationsGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreAudioPractical Considerations and Future Directions for New Treatment Strategies in SCLCRahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhDView moreMultimediaExpert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DScView moreVideoBroadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular CarcinomaGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreMultimediaPER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – NursingAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCOView moreMultimediaExpert Roundtable and Panel Discussions: Current and Future Landscape of TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCOView moreVideoShow Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast CancerAna C. Garrido-Castro, MD; Pedram Razavi, MD, PhDView moreAudioNavigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New OptionsRahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhDView moreVideoMedical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk AssessmentJason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MDView moreMultimediaReady for Radioligand Therapy? Patient Selection and Sequencing SimplifiedJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaWorking Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary CareJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaBURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate CancerJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaImaging Matters: Decoding PSMA PET for Better Decision-MakingJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaRadioligand Therapy 101: The Science Behind the StrategyJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreVideo Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease ContinuumTina Cascone, MD, PhD; Christina Baik, MD, MPH; David Planchard, MD, PhDView moreMultimediaCommunity Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary TeamYana G. Najjar, MD; Sapna Patel, MDView moreVideoA New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCsSandip Patel, MD, FASCO; Myung-Ju Ahn, MD; Giannis Mountzios, MD, MSc, PhD; Zofia Piotrowska, MD, MHSView moreVideoNavigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVOSriniVas R. Sadda, MD, FARVO; Mark R. Barakat, MD, FASRS; David A. Eichenbaum, MD, FASRSView moreVideoEnhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment StrategiesAna Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACPView moreVideo(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient OutcomesMichelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPOView more Advertisement Advertisement Trending on OncLive1Daraxonrasib Monotherapy Elicits Meaningful Responses in Previously Treated, RAS-Mutated Pancreatic Cancer2ASCO 2026 TNBC Deep Dive: Breast Cancer Experts Preview Practice-Informing Studies3FDA Completes Type A Meeting Following CRL for Tabelecleucel in EBV+ R/R Post-Transplant Lymphoproliferative Disease4Women With Bladder Cancer Face Diagnostic Delays as Symptoms Mimic UTIs, Experts Warn5Mentorship Is Key to Advance the Next Generation of Oncology Researchers